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Cost effectivenessAlthough biologic medications have demonstrated great efﬁcacy for the treatment of psoriasis, a subset of
patients fails to respond and others lose response later in the course. In treating a patient who has failed to
respond to biologic therapy, clinicians must decide between dose escalation, switching biologics, and
adding or switching to a non-biologic systemic drug or phototherapy. Although dose escalation is perhaps
the simplest strategy and generally well-tolerated, it confers a tremendous cost burden because doubling
the dosage is likely to double the wholesale price. We call for the development of rational strategies for
the pricing of dose escalation in order to minimize this phenomenon. We also call for increased transpar-
ency surrounding negotiated pricing to ensure that all patients have access to themost effective, affordable
treatment options available.
© 2016 The Authors. Published by Elsevier Inc. on behalf of Women's Dermatologic Society. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Over the past decade, biologic therapies against TNF-α, IL-17, and
IL-12/IL-23 have revolutionized the treatment of chronic inﬂamma-
tory diseases including psoriasis. Although these medications have
demonstrated favorable efﬁcacy and side effect proﬁles, a subset of
patients fails to respond and others lose response over time. Even pa-
tients who have treatment success often desire to escalate their dose
(Langley et al., 2015).
The prevalence of non-responders, deﬁned as the failure to
achieve a 75% reduction in Psoriasis Area and Severity Index (PASI)
scores by week 12-16 of therapy, ranged from 51-66% for etanercept
(Papp et al., 2005; Tyring et al., 2006), 20-32% for adalimumab
(Menter et al., 2008; Saurat et al., 2008; Thaçi et al., 2010), 24-34%
for ustekinumab (Leonardi et al., 2008; Papp et al., 2008), 18-33%
for secukinumab (Langley et al., 2014), and 11-19% for ixekizumabant from funding agencies in
estigator for Amgen, Abbvie
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2016(Gordon et al., 2016) in Phase III clinical trials. When treating a pa-
tient who has failed to respond to biologic therapy, which in the
United States has usually been preceded by systemic medications
per insurers’ appropriateness criteria, cliniciansmust decide between
dose escalation, switching biologics, and adding or switching to a
non-biologic systemic drug or phototherapy. In this era of renewed
focus on cost and quality, this decision becomes increasingly impor-
tant, especially because psoriasis patients may be taking these
drugs for several decades.
Although dose escalation is perhaps the simplest strategy and has
been shown to be well-tolerated in the majority of patients, even
when outside labeling by the U.S. Food and Drug Administration
(FDA; Brezinski and Armstrong, 2012), it confers a tremendous cost
burden because doubling the dosage also doubles the wholesale
price (RedBook Online). For example, the maintenance dose of
etanercept is 50 mg weekly (Papp et al., 2005; Tyring et al., 2006),
which costs approximately $53,909 per year in the United States. In-
creasing the dose to 50mg twiceweekly doubles the cost to $107,818
per year. Transitioning to another biologic, such as adalimumab or
ustekinumab, is a far more cost-effective strategy with an annual
cost that is approximately equivalent (RedBook Online; Table 1).
This issue is further complicated by the weight-based dosing of
ustekinumab. For patients who weigh ≤100 kg, the maintenancematologic Society. This is an open access article under the CC BY-NC-ND license
escalation of biologics in an era of cost containment: the need for a
), http://dx.doi.org/10.1016/j.ijwd.2016.09.003
Table 1
Costs of biologic drugs used to treat psoriasis, including the initial year of therapy, maintenance dosing, and escalated dosing
Initial Dosing 1st Year Cost
of Therapy
Maintenance Dosing Annual Cost Escalated Dosing Annual Cost
Etanercept 50 mg twice weekly for 3 months,
then 50 mg weekly
$67,386 50 mg weekly $53,909 50 mg twice weekly $107,818
Adalimumab 80 mg once, then 40 mg every other week $58,045 40 mg every other week $53,899 40 mg weekly $107,798
Ustekinumab ≤ 100 kg: 45 mg at weeks 0 & 4,
then every 12 weeks
$58,966 45 mg every 12 weeks $39,311 90 mg every 12 weeks $78,622
N 100 kg:
90 mg at Week 0 and Week 4,
then every 12 weeks
$117,933 90 mg every 12 weeks $78,622 90 mg every 8 weeks $117,933
Secukinumab 300 mg weekly for 5 weeks,
then 300 mg every 4 weeks
$70,195 300 mg every 4 weeks $57,033
Option to decrease to
150 mg every 4 weeks
⁎$28,517
Ixekizumab 160 mg once, then 80 mg every
2 weeks for 12 weeks, then 80 mg
every 4 weeks
$83,714 80 mg every 4 weeks $59,093 80 mg every 2 weeks $118,185
Notes: Prices reﬂect average wholesale prices and may not include negotiated rebates or other discounts. Actual patient copays may be discordant with health system costs.
⁎ The 150 mg package is the same price as the 300 mg package, but the 300 mg package could theoretically be split into two 150 mg doses to decrease costs.
2 KT. Shahwan, AB. Kimball / International Journal of Women's Dermatology xxx (2016) xxx–xxxdose is 45mg every 12 weeks (a cost of $39,311 per year), which can
later be escalated to 90 mg every 12 weeks if necessary (a cost of
$78,622 per year). Patients who weigh more than 100 kg, however,
initiate the higher dose from the beginning. Escalating to 90 mg
every 8 weeks may improve efﬁcacy in these patients, however, this
dose is not FDA-approved and costs approximately $117,933 per
year (Leonardi et al., 2008; Papp et al., 2008; RedBook Online).
Interestingly, treatment with secukinumab is designed to avoid
dose escalation. All patients are initiated on 300 mg weekly for 5
weeks, followed by 300 mg every 4 weeks, which may later beFig. 1. Treatment algorithm for patients with psoriasis who fail to respond to initial biologic t
over time include dose escalation, addition of a systemic drug or phototherapy, or transitio
Please cite this article as: Shahwan KT, Kimball AB, Managing the dose
rational strategy, International Journal of Women's Dermatology (2016decreased to 150 mg every 4 weeks in some patients. The annual
cost of maintenance therapy for patients who remain on the
300 mg dose is approximately $57,033. Although this is one of the
more expensive options, there is at least the reassurance that the
cost will not double in the future due to dose escalation. In addition,
the annual cost for patients who maintain the 150 mg dose is only
$28,517, because even though the 150mg and 300mg dose packages
are the same price, patients could theoretically get around this by
purchasing the 300 mg package and administering the contents as
two separate 150 mg doses (Langley et al., 2014; RedBook Online).herapy. Treatment options for patients who fail initial biologic therapy or lose response
n to a different biologic.
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3KT. Shahwan, AB. Kimball / International Journal of Women's Dermatology xxx (2016) xxx–xxxThese considerations could lead to treatment algorithms de-
signed to mimimize costs, which favor switching biologics over
dose escalation (Figure 1). Unfortunately, although this is more af-
fordable, there are potential clinical consequences such as the de-
velopment of anti-drug antibodies (Hsu and Armstrong, 2013),
which can limit a patient’s future treatment options. Switching
to a biosimilar will also become an option in the future as these
drugs emerge on the market. Unfortunately, they are only expect-
ed to decrease costs by 20-40% (Rumore and Vogenberg, 2016),
and their long-term safety and efﬁcacy have yet to be determined.
Another option is to add or switch to a systemic medication such
as methotrexate, which carries the risk of cumulative toxicity
(Cather and Crowley, 2014). Starting methotrexate at the time of
biologic initiation may also improve response and prevent the
need for dose escalation later on, however clinicians should keep
in mind the trade-off between any potential cost reduction and
the safety proﬁle of methotrexate.
In this era of increasingly hard choices, we have to ﬁght to pre-
serve access for our patients. Biologic drugs are expensive to develop,
and the United States subsidizes these drugs for the rest of theworld,
making it an immense challenge to control prices. However, somepa-
tients may be best served by dose escalation, and we need to main-
tain affordability. There should also be more transparency around
cost. In some cases, dose escalation may actually be cheaper because
of negotiated pricing, but it is difﬁcult for physicians and even health
care systems to get access to this data.
In conclusion, biologics have demonstrated great success in the
treatment of psoriasis, but carrywith them a substantial cost burden.
This is especially true for patients who fail to respond to starting
doses, because dose escalation typically doubles the price of themed-
ication. As a result, clinicians may be compelled to switch to a differ-
ent biologic without ﬁrst attempting to increase the dose. Moving
forward, our ﬁeld should support efforts to develop rational strate-
gies for the pricing of dose escalation in order to minimize this phe-
nomenon. These strategies would be substantially improved as well
if there were increased transparency surrounding negotiated pricing,
whichwould help ensure that all patients have access to themost ef-
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